Autologous hematopoietic stem cells for refractory Crohn's disease

作者：DiNicola C A; Zand A; Hommes D W^*

来源：Expert Opinion on Biological Therapy, 2017, 17(5): 555-564.

DOI：10.1080/14712598.2017.1305355

• Crohn's disease (CD)
• autologous hematopoietic stem cell transplant (AHSCT)
• hematopoietic stem cells (HSC)
• autoimmune diseases
• immune system

Introduction: Autologous hematopoietic stem cells are gaining ground as an effective and safe treatment for treating severe refractory Crohn's disease (CD). Autologous hematopoietic stem cell therapy (AHSCT) induces resetting of the immune system by de novo regeneration of T-cell repertoire and repopulation of epithelial cells by bone-marrow derived cells to help patients achieve clinical and endoscopic remission.Areas covered: Herein, the authors discuss the use of AHSCT in treating patients with CD. Improvements in disease activity have been seen in patients with severe autoimmune disease and patients with severe CD who underwent AHSCT for a concomitant malignant hematological disease. Clinical and endoscopic remission has been achieved in patients treated with AHSCT for CD. The only randomized trial published to date, the ASTIC Trial, did not support further use of AHSCT to treat CD. Yet, critics of this trial have deemed AHSCT as a promising treatment for severe refractory CD.Expert opinion: Even with the promising evidence presented for HSCT for refractory CD, protocols need to be refined through the collaboration of GI and hemato-oncology professionals. The goal is to incorporate safe AHSCT and restore tolerance by delivering an effective immune cease fire' as a treatment option for severe refractory CD.

• 出版日期2017-5